Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data37
FAK inhibitors in cancer, a patent review – an update on progress37
Malaria transmission blocking compounds: a patent review37
The role of patent analysis in target selection36
Update on mGlu4 modulator patents: 2017 to present34
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)33
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)33
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)29
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review24
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
An updated patent review of AKT inhibitors (2020 – present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)22
A patent review of MAPK inhibitors (2018 – present)21
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201320
Inhibition of GTPase KRAS G12D : a review of patent literature20
PDE1 inhibitors: a review of the recent patent literature (2008-present)20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Antiprotozoal drugs: challenges and opportunities19
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)19
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review18
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)18
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
An updated patent review of MALT1 inhibitors (2021–present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent review of IDH1 inhibitors (2018-present)15
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)14
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature14
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders14
Antimalarial drugs: what’s new in the patents?13
Dopamine D3 receptor ligands: a patent review (2014–2020)13
A patent and literature review of CDK12 inhibitors13
Biofilm and bacterial membrane vesicles: recent advances13
An updated patent review of EZH2 inhibitors (2024–present)12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)12
Are patents important indicators of innovation for Chagas disease treatment?12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa11
An updated patent review of TRPA1 antagonists (2020 – present)11
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)11
The patent review of the biological activity of tropane containing compounds11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Correction10
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience10
Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages9
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)9
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)9
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)9
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)9
A patent review of selective CDK9 inhibitors in treating cancer8
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)8
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
A patent review of BRD4 inhibitors (2020–present)8
Rho kinase inhibitors: a patent review (2017–2023)8
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)8
A patent review of CXCR7 modulators (2019-present)8
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published8
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)7
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)7
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)7
An updated patent review on monoamine oxidase (MAO) inhibitors7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)7
A patent perspective of antiangiogenic agents7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
Nurr1 modulators – a patent review (2019–present)7
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)7
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)7
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
Pitfalls in patenting academic CAR-T cells therapy6
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
Recent advances in the development of STING inhibitors: an updated patent review6
A patent review of xanthine oxidase inhibitors (2021–present)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
A review of the patent literature surrounding TRPV1 modulators5
Proteasome inhibitors as anticancer agents5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
Natural products as a source of new anticancer chemotypes5
An updated patent review of stimulator of interferon genes agonists (2021 – present)5
An updated patent review of glutaminase inhibitors (2019–2022)5
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
An updated patent review of BRD4 degraders5
Anticancer drugs: where are we now?5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
A patent review of adenosine A2Breceptor antagonists (2016-present)5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)4
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)4
PIM kinase inhibitors: an updated patent review (2016-present)4
A patent review of CHK1 inhibitors (2019 – present)4
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)4
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)4
Update on JNK inhibitor patents: 2015 to present4
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)4
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)4
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)4
CBL-B – An upcoming immune-oncology target4
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)4
BET inhibitors: an updated patent review (2018–2021)4
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections4
MEK inhibitors in oncology: a patent review and update (2016 – present)4
0.02803111076355